Not admitted · Not a forecast
Rules 1.1.0 · as of 14 Sep 2026
Owen Scott Muir · Said 23 Feb 2026 · owen-2090
Quote
Not a forecast
“I am neither disinterested in the work Definium is doing nor a cheerleader, because I don't know if it's gonna work yet. We need more top line data, but as I wrote in my 2025 review of LSD published in the American Journal of Therapeutics last year, the early data is promising.”
Intro disclosure. The author, a long-time MindMed shareholder and past investigator with the company, states his stance on MM-120 (Lysergide Tartrate, an oral dissolving LSD tablet) for generalized anxiety disorder, which is in phase III trials: outcome unknown, more top-line data needed, early data promising.
Descriptive, retrospective, or a statement of preference; no future state asserted.